What if aging were not irreversible? Longevity enters a new era
We are living through an extraordinary historical moment: for the first time, humanity is beginning to ask itself something that, until very recently, belonged only to the realm of science fiction. What if aging were not irreversible?
The news went almost unnoticed. The media picked it up only in passing, and yet it marks a before and after: in 2026, the FDA authorized the first clinical trial in humans based on partial cellular reprogramming through the so-called Yamanaka factors.
This is not about curing aging. Nor is it about achieving immortality. But it is about something that, barely a decade ago, would have seemed like science fiction: trying to rejuvenate damaged human cells in order to restore part of their lost functionality.
The trial, promoted by the company Life Biosciences, will use a gene therapy based on three of the Yamanaka factors —Oct4, Sox2 and Klf4— to treat age-related degenerative diseases of the optic nerve.
Behind this research lies a deeply disturbing idea: that cellular aging may not be only wear and tear, but also altered information. And that, in theory, that information could be reset.
The discovery that changed biology
The Yamanaka factors were identified by the Japanese scientist Shinya Yamanaka, who showed that an adult cell could return to an almost embryonic state through the activation of four specific genes. The discovery revolutionized modern biology and earned him the Nobel Prize. But it also opened an unsettling door: if a cell can go back, how far back could an entire organism go?
Since then, experiments have continued to advance. In 2016, researchers at the Salk Institute managed to partially rejuvenate mice with premature aging through controlled cycles of expression of the OSKM factors. The animals showed improvements in tissues and physiological functions, and increased their survival. More recently, different studies have shown improvements in muscle regeneration, nervous tissue, memory and visual function in aged mice.
When the solution becomes the problem
But playing at resetting cells has its risks. When reprogramming is carried out completely, cells can lose their identity and turn into tumors known as teratomas. Some early experiments literally ended with mice full of tumor masses.
That is why today research focuses on so-called “partial reprogramming”: rejuvenating without completely erasing the identity of each cell. Making it younger, but without turning it back into an undifferentiated stem cell.
And this is where science begins to brush against something almost philosophical. Because, for thousands of years, human beings assumed that aging was a law as inevitable as gravity. It could be delayed, disguised or accepted with dignity. But not reversed.
Now, for the first time, that boundary is beginning to move.
It is not just science: it is a race
Some scientists already speak of “epigenetic rejuvenation.” Others, more cautiously, prefer to refer to advanced cellular repair. Meanwhile, figures linked to the transhumanist movement have for years defended the idea that aging is simply a technical problem still waiting to be solved. Tech billionaires are investing astronomical sums in laboratories such as Altos Labs in California, where some of the world’s leading experts in cellular reprogramming are working.
The question no longer seems to be whether we will manage to intervene in aging. The question is how far.
Because even if these treatments were to work someday, a much harder question would remain: what does it really mean to live longer?
The Catalan Maria Branyas Morera, considered the longest-lived person in Spain, reached the age of 117. Although before her, the Frenchwoman Jeanne Calment still holds the world record for human longevity, at 122 years and 164 days. For decades, many scientists thought that this biological ceiling was practically impossible to break through. Today, that certainty is wavering.
Cellular signaling: when cells stop listening to one another
In Spain, some physicians and researchers are already exploring pathways related to cellular regeneration and molecular signaling. The orthopedic surgeon Pedro Guillén has spent years researching regenerative therapies applied to cartilage and joints. And voices such as that of Dr. Humberto Loscertales insist that much of aging has to do with progressive failures in cellular communication, inflammation and the loss of the body’s regenerative capacity.
According to Loscertales, the human body functions like an immense network of biological signaling. Cells do not work in isolation: they constantly communicate through chemical, electrical and molecular signals that coordinate essential functions such as tissue repair, immune balance or inflammation control. During youth, that communication is precise and efficient.
As the years pass, part of that signaling begins to deteriorate. The cells are still present, but some stop “listening” correctly; others send the wrong signals; others lose their capacity to respond. The organism gradually enters into a kind of biological noise: inflammation increases, regenerative capacity decreases and tissues begin to function worse.
That is why Loscertales insists that the goal should not be only to eliminate aged cells or replace damaged tissues, but to correctly signal again those cells that have stopped doing so properly. To restore that lost communication so that certain cells can recover functions that, in theory, they still retain, but that have been deactivated or altered over time.
And this is precisely where the Yamanaka factors generate so much interest within the scientific community. Because, in a way, they act on that cellular memory. What they do is reactivate biological programs that seemed to have been switched off. As if certain cells still retained the memory of how to repair, regenerate or function better… but needed to receive the right signal again.
A door that perhaps can no longer be closed
We are still very far from rejuvenating an entire body. Probably much farther still from defeating death, if that ever proves possible. But something has changed forever in this debate.
Until recently, longevity meant accepting the passage of time and trying to arrive in the best possible condition. Today we are beginning to enter a different stage: one in which science not only wants to slow deterioration, but to intervene directly in the biological mechanisms of aging.
And perhaps that explains the strange feeling that is beginning to hover around this debate. It is not exactly hope. Nor is it fear. It is something more like the intuition that humanity has just crossed a door from which, perhaps, there may be no turning back.
Fuentes:
